We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Restoring Movement: How Polylaminin is Revolutionizing Spinal Cord Injury Treatment

MedXY Editorial Team•Feb 7, 2026•Neurology
neurologyregenerative medicinespinal cord injury

The Silent Epidemic: Understanding Spinal Cord Injuries

For decades, the medical community has viewed severe spinal cord injuries (SCI) as an irreversible sentence. When the delicate bundle of nerves that transmits signals between the brain and the body is severed or crushed, the result is often permanent paralysis. Unlike other tissues in the body, the central nervous system has a notoriously limited capacity for self-repair. Once neurons are disconnected, the body forms a glial scar—a dense biological barrier that prevents new axons from crossing the site of the injury. This physical and chemical wall turns a temporary trauma into a lifelong condition. However, a groundbreaking discovery from the Federal University of Rio de Janeiro (UFRJ) in Brazil is now challenging this scientific dogma. Led by Professor Tatiana Sampaio, a team of researchers has developed a therapeutic protein called Polylaminin. This compound has demonstrated a remarkable ability to bridge the gap in damaged spinal cords, allowing nerves to reconnect and restoring sensation and movement to patients who were once told they would never walk again.

A Visionary Discovery: From Placenta to Neural Pathways

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Metabolic Regulation of Human Hematopoietic Stem and Progenitor Cell Regeneration by l-Carnitine: Mechanistic Insights and Therapeutic ImplicationsThis review synthesizes evidence revealing l-carnitine’s pivotal role in human hematopoietic stem and progenitor cell regeneration via fatty acid oxidation, highlighting metabolic profiling advances and translational potential for regAug 12, 2026Digital Vestibular Rehabilitation After Acute Vertigo: What a Negative Superiority Trial MeansA 2026 PLOS One superiority trial found that internet-based vestibular rehabilitation was not superior to structured written instructions after acute vertigo. The result is clinically useful because the comparator was active, adherence was Jun 16, 2026Rural-Urban Disparities in Epilepsy Outcomes in the United StatesA national U.S. study found that patients with epilepsy from rural counties had worse hospital outcomes, including higher mortality, more status epilepticus, longer stays, and less EEG use, highlighting access-related disparities.Jun 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Acetazolamide Fails to Improve Gait in Idiopathic Normal Pressure Hydrocephalus: Swedish DRAIN Trial
In a Swedish randomized trial, low-dose acetazolamide did not improve gait in patients with idiopathic normal pressure hydrocephalus and caused more side effects than placebo, arguing against routine use as medical therapy.
Jun 5, 2026
Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical TrialIn a phase 3 trial, once-daily tavapadon improved motor symptoms in people with early Parkinson disease and was generally well tolerated, with nausea, headache, and dizziness as the most common side effects.May 20, 2026
Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseIn adults with MOGAD, stopping maintenance therapy was associated with a low 1-year relapse risk, especially after longer treatment and a longer relapse-free interval. The findings support individualized decisions and close follow-up after May 13, 2026